Detailed Information on Publication Record
2023
Substituted aminothiazoles as inhibitors of nucleases
PARUCH, Kamil, Benoit Jean-Pierre CARBAIN, Štěpán HAVEL, Jiří DAMBORSKÝ, Jan BREZOVSKÝ et. al.Basic information
Original name
Substituted aminothiazoles as inhibitors of nucleases
Name (in English)
Substituted aminothiazoles as inhibitors of nucleases
Authors
PARUCH, Kamil (203 Czech Republic, belonging to the institution), Benoit Jean-Pierre CARBAIN (250 France, belonging to the institution), Štěpán HAVEL (203 Czech Republic, belonging to the institution), Jiří DAMBORSKÝ (203 Czech Republic, belonging to the institution), Jan BREZOVSKÝ (203 Czech Republic, belonging to the institution), Lukáš DANIEL (203 Czech Republic, belonging to the institution), Alexandra SISÁKOVÁ (703 Slovakia, belonging to the institution), Fedor NIKULENKOV (203 Czech Republic, belonging to the institution) and Lumír KREJČÍ (203 Czech Republic, belonging to the institution)
Edition
Number: IL277866, Publisher: Israel Patent Office, Place of publication: Jerusalem, Owner's name: Masarykova univerzita, 2023
Other information
Language
Yiddish
Type of outcome
Patent
Field of Study
30107 Medicinal chemistry
Country of publisher
Israel
Confidentiality degree
není předmětem státního či obchodního tajemství
References:
RIV identification code
RIV/00216224:14310/23:00132705
Organization unit
Faculty of Science
Keywords in English
DNA; propanamide; nuclease
Tags
Tags
International impact
Změněno: 6/8/2024 10:37, Mgr. Marie Šípková, DiS.
V originále
Compounds represented by the structural formula (1) R1, R2, R3, R4, R5, R6 are inhibitors of nucleases, and are useful in particular in a method of treatment and/or prevention of proliferative diseases, neurodegenerative diseases, and other genomic instability associated diseases.
In English
Compounds represented by the structural formula (1) R1, R2, R3, R4, R5, R6 are inhibitors of nucleases, and are useful in particular in a method of treatment and/or prevention of proliferative diseases, neurodegenerative diseases, and other genomic instability associated diseases.